A proteomic study identifies different levels of light chain ferritin in corticobasal degeneration and progressive supranuclear palsy

Abdul Shukkur Ebrahim, Jayanarayan Kulathingal, Melissa E Murray, Monica Casey-Castanedes, Dennis W Dickson, Shu Hui Yen, Daniel Sevlever

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Clinical and pathological evidence supports the notion that corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) are distinct, but overlapping neurodegenerative tauopathies. Although both disorders are characterized by abnormal accumulation of 4-repeat tau, they display distinct proteolytic profiles of tau species and they have distinct astrocytic lesions, astrocytic plaques in CBD and tufted astrocytes in PSP. To investigate other differences between these two disorders at the molecular level, we compared the profiles of proteins from caudate nucleus of CBD and PSP by quantitative two-dimensional difference gel electrophoresis. Twenty-one protein spots differentially expressed in CBD and PSP were dissected for mass spectrometry (MS). One of the spots was identified by MS to contain light chain (LC) ferritin. Western blot analysis verified the presence of LC ferritin in this spot and showed that this protein was two-fold higher in caudate of CBD than that of PSP samples. These results were confirmed by LC ferritin immunohistochemistry. Co-labeling of caudate nucleus with tau and LC ferritin antibodies showed the presence of LC ferritin immunoreactivity in astrocytic plaques of CBD, but minimal labeling of tufted astrocytes in PSP. This difference did not reflect the extent of gliosis. Analysis of other brain regions in CBD and PSP showed no difference in LC ferritin levels. Together the data suggest that LC ferritin is a unique marker of astrocytic lesions in CBD, adding further support to the notion that CBD and PSP are distinct clinicopathologic entities.

Original languageEnglish (US)
Pages (from-to)727-736
Number of pages10
JournalActa Neuropathologica
Volume122
Issue number6
DOIs
StatePublished - Dec 2011

Fingerprint

Apoferritins
Progressive Supranuclear Palsy
Proteomics
Caudate Nucleus
Astrocytes
Mass Spectrometry
Two-Dimensional Difference Gel Electrophoresis
Tauopathies
Proteins
Gliosis
Western Blotting
Immunohistochemistry
Antibodies

Keywords

  • CBD
  • DIGE
  • Ferritin
  • Proteomics
  • PSP

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cellular and Molecular Neuroscience

Cite this

A proteomic study identifies different levels of light chain ferritin in corticobasal degeneration and progressive supranuclear palsy. / Ebrahim, Abdul Shukkur; Kulathingal, Jayanarayan; Murray, Melissa E; Casey-Castanedes, Monica; Dickson, Dennis W; Yen, Shu Hui; Sevlever, Daniel.

In: Acta Neuropathologica, Vol. 122, No. 6, 12.2011, p. 727-736.

Research output: Contribution to journalArticle

Ebrahim, Abdul Shukkur ; Kulathingal, Jayanarayan ; Murray, Melissa E ; Casey-Castanedes, Monica ; Dickson, Dennis W ; Yen, Shu Hui ; Sevlever, Daniel. / A proteomic study identifies different levels of light chain ferritin in corticobasal degeneration and progressive supranuclear palsy. In: Acta Neuropathologica. 2011 ; Vol. 122, No. 6. pp. 727-736.
@article{dbe464ea455b4557b220cdd1a050bec7,
title = "A proteomic study identifies different levels of light chain ferritin in corticobasal degeneration and progressive supranuclear palsy",
abstract = "Clinical and pathological evidence supports the notion that corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) are distinct, but overlapping neurodegenerative tauopathies. Although both disorders are characterized by abnormal accumulation of 4-repeat tau, they display distinct proteolytic profiles of tau species and they have distinct astrocytic lesions, astrocytic plaques in CBD and tufted astrocytes in PSP. To investigate other differences between these two disorders at the molecular level, we compared the profiles of proteins from caudate nucleus of CBD and PSP by quantitative two-dimensional difference gel electrophoresis. Twenty-one protein spots differentially expressed in CBD and PSP were dissected for mass spectrometry (MS). One of the spots was identified by MS to contain light chain (LC) ferritin. Western blot analysis verified the presence of LC ferritin in this spot and showed that this protein was two-fold higher in caudate of CBD than that of PSP samples. These results were confirmed by LC ferritin immunohistochemistry. Co-labeling of caudate nucleus with tau and LC ferritin antibodies showed the presence of LC ferritin immunoreactivity in astrocytic plaques of CBD, but minimal labeling of tufted astrocytes in PSP. This difference did not reflect the extent of gliosis. Analysis of other brain regions in CBD and PSP showed no difference in LC ferritin levels. Together the data suggest that LC ferritin is a unique marker of astrocytic lesions in CBD, adding further support to the notion that CBD and PSP are distinct clinicopathologic entities.",
keywords = "CBD, DIGE, Ferritin, Proteomics, PSP",
author = "Ebrahim, {Abdul Shukkur} and Jayanarayan Kulathingal and Murray, {Melissa E} and Monica Casey-Castanedes and Dickson, {Dennis W} and Yen, {Shu Hui} and Daniel Sevlever",
year = "2011",
month = "12",
doi = "10.1007/s00401-011-0888-x",
language = "English (US)",
volume = "122",
pages = "727--736",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - A proteomic study identifies different levels of light chain ferritin in corticobasal degeneration and progressive supranuclear palsy

AU - Ebrahim, Abdul Shukkur

AU - Kulathingal, Jayanarayan

AU - Murray, Melissa E

AU - Casey-Castanedes, Monica

AU - Dickson, Dennis W

AU - Yen, Shu Hui

AU - Sevlever, Daniel

PY - 2011/12

Y1 - 2011/12

N2 - Clinical and pathological evidence supports the notion that corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) are distinct, but overlapping neurodegenerative tauopathies. Although both disorders are characterized by abnormal accumulation of 4-repeat tau, they display distinct proteolytic profiles of tau species and they have distinct astrocytic lesions, astrocytic plaques in CBD and tufted astrocytes in PSP. To investigate other differences between these two disorders at the molecular level, we compared the profiles of proteins from caudate nucleus of CBD and PSP by quantitative two-dimensional difference gel electrophoresis. Twenty-one protein spots differentially expressed in CBD and PSP were dissected for mass spectrometry (MS). One of the spots was identified by MS to contain light chain (LC) ferritin. Western blot analysis verified the presence of LC ferritin in this spot and showed that this protein was two-fold higher in caudate of CBD than that of PSP samples. These results were confirmed by LC ferritin immunohistochemistry. Co-labeling of caudate nucleus with tau and LC ferritin antibodies showed the presence of LC ferritin immunoreactivity in astrocytic plaques of CBD, but minimal labeling of tufted astrocytes in PSP. This difference did not reflect the extent of gliosis. Analysis of other brain regions in CBD and PSP showed no difference in LC ferritin levels. Together the data suggest that LC ferritin is a unique marker of astrocytic lesions in CBD, adding further support to the notion that CBD and PSP are distinct clinicopathologic entities.

AB - Clinical and pathological evidence supports the notion that corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) are distinct, but overlapping neurodegenerative tauopathies. Although both disorders are characterized by abnormal accumulation of 4-repeat tau, they display distinct proteolytic profiles of tau species and they have distinct astrocytic lesions, astrocytic plaques in CBD and tufted astrocytes in PSP. To investigate other differences between these two disorders at the molecular level, we compared the profiles of proteins from caudate nucleus of CBD and PSP by quantitative two-dimensional difference gel electrophoresis. Twenty-one protein spots differentially expressed in CBD and PSP were dissected for mass spectrometry (MS). One of the spots was identified by MS to contain light chain (LC) ferritin. Western blot analysis verified the presence of LC ferritin in this spot and showed that this protein was two-fold higher in caudate of CBD than that of PSP samples. These results were confirmed by LC ferritin immunohistochemistry. Co-labeling of caudate nucleus with tau and LC ferritin antibodies showed the presence of LC ferritin immunoreactivity in astrocytic plaques of CBD, but minimal labeling of tufted astrocytes in PSP. This difference did not reflect the extent of gliosis. Analysis of other brain regions in CBD and PSP showed no difference in LC ferritin levels. Together the data suggest that LC ferritin is a unique marker of astrocytic lesions in CBD, adding further support to the notion that CBD and PSP are distinct clinicopathologic entities.

KW - CBD

KW - DIGE

KW - Ferritin

KW - Proteomics

KW - PSP

UR - http://www.scopus.com/inward/record.url?scp=82355175222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82355175222&partnerID=8YFLogxK

U2 - 10.1007/s00401-011-0888-x

DO - 10.1007/s00401-011-0888-x

M3 - Article

C2 - 22012136

AN - SCOPUS:82355175222

VL - 122

SP - 727

EP - 736

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 6

ER -